$CLMB

BTIG reiterated a Buy rating on Climb Bio with a $32 price target, implying 263.2% upside from the Oct 26 close. The firm cited positive early trial data for budoprutug and a favorable safety profile for CLYM116, boosting confidence in the company's pipeline.

Climb Bio (NASDAQ: CLYM) reported initial Phase 2 trial results for its kidney-disease treatment, PrisMN, showing 38% immunologic remission in the low-dose cohort and a 70% reduction in disease-linked antibodies. The company plans to release additional data in 2027. Climb shares closed at $10.19 before the announcement. The trial aims to identify a dose for pivotal development, with no serious adverse events reported.

Climb Global Solutions acquired NeoVAD, a French IT distributor, for approximately €16.0 million. The deal, effective October 21, 2026, expands Climb's presence in cybersecurity, cloud services, and virtualization in France, according to an SEC filing.

Climb Global Solutions, Inc. (CLMB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 ​ ​ ​ Climb Global Solutions Acquires NeoVAD, Building Greater Scale in France Acquisition Expands Climb ’ s European Platform and Deepens Strategic Vendor Relationships Transaction Expected to be Accretive to Earnings per Share and Adjusted EBITDA ​ EATONTOWN, N.J.,

Climb Global Solutions (CLMB) acquired NeoVAD, a France-based distributor, for approximately €16.0M. The company expects the deal to boost earnings and adjusted EBITDA, expanding its European footprint.

Climb Global Solutions (CLMB) announced a North American distribution agreement with Netwrix, a data and identity security company. The deal allows Climb's partners to resell Netwrix solutions, including the 1Secure platform. Netwrix serves over 13,000 organizations globally. Climb CEO Dale Foster stated the agreement aligns with partner requests for data visibility and access control capabilities.

Climb Global Solutions (NASDAQ:CLMB) reported Q2 adjusted EBITDA of $11.3 million, roughly flat year over year, but effective margin fell to 37.5% from 43.3%. Management cited a higher tax rate and about $500,000 in nonrecurring expenses. The company expanded vendor/distribution deals including Ivanti and Checkmk, broadened LogicMonitor and added Quantum, and said Fortinet gross billings rose sharply. Cash was $56.6 million.

Climb Global Solutions (NASDAQ:CLMB) reported Q2 2026 results for the quarter ended June 30, 2026. Net sales rose 9% to $174.2M and gross billings increased 17% to $587.3M. Gross profit grew 15% to $30.2M. Net income was $5.5M, or $0.30 diluted EPS, vs $6.0M. Adjusted EBITDA was $11.3M. Cash was $56.6M and the company had no debt.

Climb Global Solutions, Inc. (CLMB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Climb Global Solutions Reports Second Quarter 2026 Results Net Sales up 9% to $174.2 Million; Gross Billings up 17% to $587.3 Million; Gross Profit up 15% to $30.2 Million EATONTOWN, N.J., July 29, 2026 – Climb Global Solutions, Inc. (NASDAQ:CLMB) (“Climb” or the “Co

Climb Global Solutions, Inc. (CLMB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. clmb20260623_8k.htm false 0000945983 0000945983 2026-06-23 2026-06-23 ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ​ ​ FORM 8-K ​ ​ CURRENT REPORT ​ Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ​ Date of Report (Date of earli